Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy

HER2-positive gastric cancer (GC) makes up 15–20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qi, Xu, Xiaoqing, Tang, Haimeng, Yan, Junrong, Li, Jingjing, Bao, Hua, Wu, Xue, Shao, Yang, Luo, Cong, Wen, Haimin, Jin, Jianying, Ying, Jieer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113330/
https://www.ncbi.nlm.nih.gov/pubmed/37072406
http://dx.doi.org/10.1038/s41389-023-00466-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113330/
https://www.ncbi.nlm.nih.gov/pubmed/37072406
http://dx.doi.org/10.1038/s41389-023-00466-2

Ejemplares similares